Pre-made Begelomab benchmark antibody ( Whole mAb, anti-DPP4/DPP-4 therapeutic antibody, Anti-ADABP/ADCP2/CD26/DPPIV/TP103 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-054

Pre-Made Begelomab biosimilar, Whole mAb, Anti-DPP4/DPP-4 Antibody: Anti-ADABP/ADCP2/CD26/DPPIV/TP103 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

A monoclonal antibody against the human dipeptidyl peptidase 4 (dipeptidylpeptidase IV, DPPIV, DPP4; CD26), with potential activity against graft-versus-host disease (GvHD). Upon administration, begelomab binds to CD26 expressed on T-cells. This inhibits the stimulation of T-cells and may prevent GvHD.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-054-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Begelomab biosimilar, Whole mAb, Anti-DPP4/DPP-4 Antibody: Anti-ADABP/ADCP2/CD26/DPPIV/TP103 therapeutic antibody
INN Name Begelomab
TargetDPP-4
FormatWhole mAb
DerivationMouse
Species ReactivityHuman
CH1 IsotypeIgG2b
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II/III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesADIENNE
Conditions Approvedna
Conditions ActiveGraft-versus-host disease
Conditions Discontinuedna
Development Techna